Posted On: 06/13/2016 7:09:34 AM
Post# of 1459
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Looks like they are gonna be at AAIC 2016.
New Exploratory Alzheimer’s Drug Anavex 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients
Metro Toronto Convention Centre Room: Hall D/E
P1-046
New Exploratory Alzheimer’s Drug Anavex 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients
9:30am-10:30am Sun, Jul 24
https://ep70.eventpilotadmin.com/web/planner....AAIC16lite
New Exploratory Alzheimer’s Drug Anavex 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients
Metro Toronto Convention Centre Room: Hall D/E
P1-046
New Exploratory Alzheimer’s Drug Anavex 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients
9:30am-10:30am Sun, Jul 24
https://ep70.eventpilotadmin.com/web/planner....AAIC16lite
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)